Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled |